...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.
【24h】

18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.

机译:18F-FDG正电子发射断层扫描在术前化学放射治疗的直肠癌中的分期和再分期。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To assess the information supplied by FDG-PET in patients with locally advanced rectal cancer both in the initial staging and in the evaluation of tumor changes induced by preoperative chemoradiation (restaging). METHODS AND MATERIALS: Twenty-five consecutive patients with rectal cancer were included, with tumor stages (c)T(2-4)N(x)M(0), during the period 1997-1999. We prospectively performed two FDG-PET scans in all patients to assess disease stage (1) at initial diagnosis and (2) presurgically, 4 to 5 weeks after protracted chemoradiation. Protracted chemoradiation was carried out during 5-6 weeks with 45-50 Gy, plus concurrent oral tegafur 1200 mg/day or 5-fluorouracil 500-1000 mg/m(2) administered as a 24-h continuous i.v. infusion on Days 1-4 and 21-25 of the radiotherapy treatment. Tumors were staged with CT in 95% of patients, whereas endorectal ultrasound was used in 90% of patients. Maximum standardized uptake value (SUVmax) was used as the quantitative parameter to estimate the tumor:tissue metabolic ratio. RESULTS: Preoperative chemoradiation significantly decreased the SUVMAX: 5.9 (mean SUVmax at initial staging) vs. 2.4 (mean SUVmax after chemoradiation) with p < 0.001. Unknown liver metastases were detected by FDG-PET in 2 patients, in 1 of them with the initial staging FDG-PET scan, and with the restaging FDG-PET scan in the other. After an average follow-up of 39 months, the value of SUVmax > or =6 allowed us to discriminate for survival at 3 years: 92% vs. 60% (p = 0.04). T downstaging (total 62%) was significantly correlated with SUVmax changes: 1.9 vs. 3.3 (p = 0.03). The degree of rectal cancer response to chemoradiation, established as mic vs. mac categories, was not associated with SUVmax differences (mean values of 2.0 vs. 2.7). CONCLUSION: Preliminary results observed suggest the potential utility of FDG-PET as a complementary diagnostic procedure in the initial clinical evaluation (8% of unsuspected liver metastases) as well as in the assessment of chemoradiation response (any T downstaged event) of locally advanced rectal cancer. Initial SUVmax might be of prognostic value related to long-term patient outcome.
机译:目的:评估FDG-PET为局部晚期直肠癌患者提供的信息,包括初步分期和术前化学放疗(再分期)引起的肿瘤变化的评估。方法和材料:1997年至1999年期间,连续25例直肠癌患者,其肿瘤分期为(c)T(2-4)N(x)M(0)。我们前瞻性地对所有患者进行了两次FDG-PET扫描,以评估疾病的阶段(1)初始诊断时和(2)术前放化疗后4至5周的术前。在5-6周内以45-50 Gy进行持久的化学放射,外加并发口服替加福1200 mg /天或5-氟尿嘧啶500-1000 mg / m(2),连续24小时连续静脉内给药。在放疗的第1-4天和第21-25天输注。 95%的患者使用CT分期肿瘤,而90%的患者使用直肠内超声。将最大标准化摄取值(SUVmax)用作定量参数,以评估肿瘤与组织的代谢比。结果:术前放化疗显着降低了SUVMAX:5.9(初始分期时的平均SUVmax)与2.4(放疗后的平均SUVmax)的p <0.001。 FDG-PET在2例患者中发现了未知的肝转移,其中1例患者进行了初始分期的FDG-PET扫描,另一例进行了重新分期的FDG-PET扫描。在平均随访39个月后,SUVmax≥6的值使我们能够区分3年生存率:92%对60%(p = 0.04)。 T降级(总计62%)与SUVmax变化显着相关:1.9 vs. 3.3(p = 0.03)。直肠癌对化学放疗的反应程度(确定为mic和mac类别)与SUVmax差异无关(平均值分别为2.0和2.7)。结论:观察到的初步结果表明,FDG-PET在初步临床评估(未怀疑肝转移的8%)以及对局部晚期直肠的化学放疗反应(任何T降低的事件)的评估中具有潜在的辅助诊断作用。癌症。最初的SUVmax可能与长期患者预后有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号